Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-11-25

Clinical Trial Update: Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms [Phase 2]

View source ↗

Summary

A Phase 2 study of temsirolimus (CCI-779) in breast cancer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Temsirolimus (temsirolimus)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2010-11-25